Skip to Content

Generic Levaquin Availability

Levaquin is a brand name of levofloxacin, approved by the FDA in the following formulation(s):

LEVAQUIN (levofloxacin - injectable;injection)

  • Manufacturer: JANSSEN PHARMS
    Approval date: December 20, 1996
    Strength(s): EQ 500MG/20ML (EQ 25MG/ML) [RLD], EQ 750MG/30ML (EQ 25MG/ML) [RLD]

LEVAQUIN (levofloxacin - solution;oral)

  • Manufacturer: JANSSEN PHARMS
    Approval date: October 21, 2004
    Strength(s): 250MG/10ML [RLD]

LEVAQUIN (levofloxacin - tablet;oral)

  • Manufacturer: JANSSEN PHARMS
    Approval date: December 20, 1996
    Strength(s): 250MG [RLD], 500MG [RLD]
  • Manufacturer: JANSSEN PHARMS
    Approval date: September 8, 2000
    Strength(s): 750MG [RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Levaquin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Taste masked liquid pharmaceutical compositions
    Patent 6,806,256
    Issued: October 19, 2004
    Inventor(s): Stephen A.; Ulrich & Karen R.; Zimm & Marc Karel Jozef; Francois & Willy Maria Albert Carlo; Dries
    Assignee(s): Ortho -McNeil Pharmaceutical, Inc.

    This invention is directed to a taste masked liquid pharmaceutical composition comprising a pharmaceutically active agent and a taste masking composition. In particular, the taste masking composition comprises a taste masking effective amount of an artificial sweetener.

    Patent expiration dates:

    • February 26, 2022
      Drug product
    • August 26, 2022
      Pediatric exclusivity

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.